You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Dow
Harvard Business School
Boehringer Ingelheim
McKesson

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Litigation Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-09-17
Court District Court, D. New Jersey Date Terminated 2018-06-25
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Cathy L. Waldor
Parties ACTAVIS PHARMA INC.
Patents 7,094,427; 7,659,254; 8,377,474; 8,454,998; 8,557,283; 9,089,607; 9,089,608; 9,463,246; 9,533,046
Attorneys MICHAEL E. PATUNAS
Firms Alston & Bird LLP
Link to Docket External link to docket
Small Molecule Drugs cited in IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2017-05-09 118 : construction of claims in U.S. Patent No. 8,377,474 (the 474 patent). Signed by Judge Stanley R. Chesler…construction of claims in U.S. Patent No. 8,377,474 (“the ’474 patent”). The Court heard oral argument…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…, “Actavis”). In this patent infringement suit involving pharmaceutical patents, the parties seek construction… It is a bedrock principle of patent law that the claims of a patent define the invention to External link to document
2017-06-08 123 limitations of the asserted claims of U.S. Patent No. 8,377,474. In the Order, the Court construed, among…U.S. Patent Nos. 8,454,998 and 9,089,607, (which are in the same patent family as the ‘474 patent and …prejudice all of its counterclaims relating to these patents, Actavis reserves its right to reassert all of … regarding the disputed limitations of the ‘474 patent claims, Impax hereby stipulates that, without waiving… Application Number 208522 do not infringe this patent as the claims are construed in the Order. 3. Moreover External link to document
2017-06-16 127 regarding the ex parte reexamination of U.S. patent No. 7,094,427, as ordered in the Court’s Order Granting…following the Patent Trial and Appeal Board Decision on Appeal. At this time, the Patent Office has not…Motion to Stay Proceedings with respect to the ‘427 patent (D.I. 47). As the Court is aware, on November 23…2015 25 June 2018 2:15-cv-06934 830 Patent None District Court, D. New Jersey External link to document
2017-10-24 145 474 patent Ex. 5, U.S. Patent No. 8,377,474 the ’427 patent Ex. 6, U.S. Patent No. 7,094,427 (no…is confirmed by U.S. Patent No. 7,094,427 (“the ’427 patent”). 6 The ’427 patent explains that “[i]nitial… the ’246 patent Ex. 3, U.S. Patent No. 9,463,246 the ’046 patent Ex. 4, U.S. Patent No. 9,533,…the ’998 patent U.S. Patent No. 8,454,998 (no longer asserted) the ’607 patent U.S. Patent No. 9,089,607… U.S. Patent Application No. 2007/0148238 patents-in-suit U.S. Patent Nos. 8,557,283; External link to document
2017-12-17 157 regarding the ex parte reexamination of U.S. Patent No. 7,094,427, as ordered in the Court’s Order Granting…with respect to the ‘427 patent (D.I. 47). On November 24, 2017, the U.S. Patent and Trademark Office issued…Reexamination Certificate cancelling all claims of the ‘427 patent, and Impax expects that certificate to issue in…formally removing the allegations regarding the ‘427 patent from the case, and expect to file something next…2015 25 June 2018 2:15-cv-06934 830 Patent None District Court, D. New Jersey External link to document
2017-12-28 162 brought claims of patent infringement of U.S. Patent No. 7,094,427 (the “’427 Patent”) against Defendants…U.S. Patent No. 7,094,427. If the proposed Stipulation of Dismissal Regarding U.S. Patent No. …Certificate cancelling all claims of U.S. Patent No. 7,094,427, enclosed please find a proposed Stipulation…Stipulation of Dismissal Regarding U.S. Patent No. 7,094,427. Defendants Actavis Laboratories FL, Inc. and … STIPULATION OF DISMISSAL REGARDING U.S. PATENT NO. 7,094,427 WHEREAS, Plaintiff Impax Laboratories External link to document
2018-01-02 165 STIPULATION AND ORDER OF DISMISSAL re: U.S. Patent No. 7,094,427, w/prejudice and w/out costs. Signed by …2015 25 June 2018 2:15-cv-06934 830 Patent None District Court, D. New Jersey External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Merck
Dow
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.